What happened with CORT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Corcept Therapeutics sells Korlym and its authorized generic to treat patients with hypercortisolism, a condition involving excess cortisol. Its sales representatives call on treating physicians, while specialty pharmacy partner Curant Health Georgia, LLC dispenses the medicines and collects insurer payments that account for nearly all company revenue. Corcept relies on outside manufacturers to supply the medicines.
These drug sales fund operations and research into treatments that modulate cortisol for cancer and other serious disorders. The development pipeline is distinct from its marketed products: the FDA declined to approve relacorilant for hypercortisolism and required additional evidence of effectiveness.
The business depends on physicians prescribing its products, insurers covering them at acceptable prices, and Curant dispensing them and collecting payment. Teva Pharmaceuticals USA, Inc. already sells a competing generic Korlym. Corcept’s products contain mifepristone but are not approved or promoted for pregnancy termination; restrictions affecting that ingredient could also limit access to its hypercortisolism treatments.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Corcept’s results hinge on hypercortisolism prescriptions and its cortisol-modulator pipeline; watch Recordati’s Isturisa and Signifor for important competition missing from this list.
Xeris Biopharma sells Recorlev for hypercortisolism, competing for patients and physician prescriptions with Corcept’s Korlym and authorized generic. Watch Recorlev sales rather than Xeris’s other medicines for signs of pressure on Corcept’s prescription business.
Teva sells generic Korlym to treat hypercortisolism, directly competing with Corcept’s branded drug and authorized generic. The patent dispute is a key development to watch: on February 19, 2026, the Federal Circuit affirmed that Teva’s proposed generic infringed neither of the two patents Corcept asserted.
Genelux is developing Olvi-Vec for patients with platinum-resistant or refractory ovarian cancer, competing for the treatment market Corcept targets with relacorilant. Watch Olvi-Vec’s U.S. Phase 3 trial results for evidence of the competing treatment’s safety and effectiveness.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report can show whether its generic Korlym is gaining traction and competing for prescriptions with Corcept’s branded and authorized-generic products.
Look for Teva’s disclosure on generic Korlym, keeping it distinct from Corcept’s sales of branded Korlym and its authorized generic. Stronger generic traction would suggest prescriptions or pricing power may be shifting to a competitor, increasing pressure on Corcept; weaker traction would suggest less pressure, but Teva’s results cannot establish Corcept’s own sales.
Corcept Therapeutics Inc. earningsThis company
Corcept’s report will show whether it can turn patient demand into more product sales now that Curant handles most of its specialty-pharmacy services.
Read net product revenue alongside any update on dispensing and product availability. Revenue growth with normalized dispensing would suggest patient demand is reaching sales again; revenue still constrained would point to a pharmacy-transition or other access bottleneck, leaving Corcept’s sales short of demand.
